Flag­ship-backed mi­cro­bio­me com­pa­ny Kalei­do Bio­sciences shuts down

Three months af­ter ini­ti­at­ing lay­offs, hit­ting pause on a planned COPD study and ter­mi­nat­ing an agree­ment with the COPD Foun­da­tion, Kalei­do Bio­sciences is now shut­ting down.

On Fri­day, the biotech’s board vot­ed to “im­me­di­ate­ly wind-down and cease all of the Com­pa­ny’s on­go­ing op­er­a­tions,” ac­cord­ing to an SEC fil­ing. CEO Daniel Menichel­la, CFO William Duke, and CSO Jo­han van Hyl­cka­ma Vlieg were let go im­me­di­ate­ly. Kalei­do’s stock price $KL­DO fell near­ly 76% to about 36 cents apiece.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER